- 4-Week # shares sold: 1,625
- 12-Week # shares sold: 8,030
- 24-Week # shares sold: 8,030
The Protalix medicine alidornase alfa is designed to help cystic fibrosis patients clear their lungs by making mucus thin and loose.
Investors ran for the exits after analysts pointed out that glowing Phase 2 study results for Corbus actually weren't that great. But a better story lies behind this biotech play.
Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.